Serum and salivary chemerin concentrations in patients with colorectal cancer and obesity
More details
Hide details
Zakład Pielęgniarstwa Chirurgicznego i Propedeutyki Chirurgii, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach
Katedra i Zakład Biologii Medycznej i Molekularnej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Katedra i Oddział Kliniczny Chirurgii Ogólnej, Kolorektalnej i Urazów Wielonarządowych, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach
Corresponding author
Dariusz Waniczek   

Zakład Pielęgniarstwa Chirurgicznego i Propedeutyki Chirurgii, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, ul. Żeromskiego 7, 41-902 Bytom
Ann. Acad. Med. Siles. 2021;75:11-17
The study was carried out with prior approval of the Ethics Committee, No. KW/0022/KBI/42/14/16/18
Chemerin is an adipokine, whose pro-inflammatory and carcinogenesis-related properties have recently been emphasized. The aim of this study was to examine the concentrations of chemerin in the serum and saliva of healthy subjects and patients with colorectal cancer (CRC) in II and III stage of TNM (tumor, node, metastasis) classification as well as to assess the relationship between the results and the clinical and pathological parameters.

Material and methods:
52 persons were qualified to the study, divided into two equal groups – control and study with cancer in stage II N0 and in stage III N+ according to TNM classification. Inside the groups, subgroups of persons with normal body weight 18.5 ≤ BMI < 25 and obese and overweight persons with a BMI ≥ 25 were distinguished. Serum and saliva chemerin concentrations were determined by immunoenzymatic methods.

The median concentrations of chemerin were significantly higher in the study group as compared to the control group both in serum (384.36 ng/ml vs. 170.53 ng/ml) and saliva (15.45 ng/ml vs. 4.57 ng/ml; p < 0.0001). In the subgroups with a BMI above and below 25, we found no significant differences in the concentrations of chemerin either group. There were no significant differences in the levels of chemerin in the serum or saliva between stage II and III stage of TNM (p = 0.82 and p = 0.52).

The assessment of serum and saliva chemerin concentrations in patients with CRC suggests that chemerin may be a valuable biomarker for early diagnosis of CRC. The influence of BMI on the results seems to be insignificant in patients with CRC. It seems that in some cases an easily accepted saliva test can replace a serum one.

Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127(12): 2893–2917, doi: 10.1002/ijc.25516.
Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003; 348(17): 1625–1638, doi: 10.1056/NEJMoa021423.
Donohoe C.L., O’Farrell N.J., Doyle S.L., Reynolds J.V. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap. Adv. Gastroenterol. 2014; 7(1): 38–50, doi: 10.1177/1756283X13501786.
Chamberland J.P., Berman R.L., Aronis K.N., Mantzoros C.S. Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans. Eur. J. Endocrinol. 2013; 169(4): 453–462, doi: 10.1530/EJE-13-0098.
Kumar J.D., Holmberg C., Kandola S., Steele I., Hegyi P., Tiszlavicz L. et al. Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells. PLoS One 2014; 9(7): e104877, doi: 10.1371/journal.pone.0104877.
Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G. et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148(10): 4687–4694, doi: 10.1210/en.2007-0175.
Erdogan S., Yilmaz F.M., Yazici O., Yozgat A., Sezer S. et al. Inflammation and chemerin in colorectal cancer. Tumour Biol. 2016; 37(5): 6337–6342, doi: 10.1007/s13277-015-4483-y.
Alkady M.M., Abdel-Messeih P.L., Nosseir N.M. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J. Med. Biochem. 2018; 37(3): 313–319, doi: 10.1515/jomb-2017-0062.
Eichelmann F., Schulze M.B., Wittenbecher C., Menzel J., Weikert C., di Giuseppe R. et al. Association of chemerin plasma concentration with risk of colorectal cancer. JAMA Netw. Open 2019; 2(3): e190896, doi: 10.1001/jamanetworkopen.2019.0896.
Wang C., Wu W.K., Liu X., To K.F., Chen G.G., Yu J. et al. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides 2014; 51: 131–138, doi: 10.1016/j.peptides.2013.10.009.
Xu C.H., Yang Y., Wang Y.C., Yan J., Qian L.H. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer. Oncotarget 2017; 8(14): 22483–22489, doi: 10.18632/oncotarget.14956.
Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S. et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm. Bowel Dis. 2010; 16(4): 630–637, doi: 10.1002/ibd.21091.
Du X.Y., Zabel B.A., Myles T., Allen S.J., Handel T.M., Lee P.P. et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin–activable fibrinolysis inhibitor), and platelets. J. Biol. Chem. 2009; 284(2): 751–758, doi: 10.1074/jbc.M805000200.
Lehrke M., Becker A., Greif M., Stark R., Laubender R.P., von Ziegler F. et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 2009; 161(2): 339–344, doi: 10.1530/EJE-09-0380.
Tan B.K., Chen J., Farhatullah S., Adya R., Kaur J., Heutling D. et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009; 58(9): 1971–1977, doi: 10.2337/db08-1528.
Bozaoglu K., Segal D., Shields K.A., Cummings N., Curran J.E., Comuzzie A.G. et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican–American population. J. Clin. Endocrinol. Metab. 2009; 94(8): 3085–3088, doi: 10.1210/jc.2008-1833.
Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R. et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. 2010; 72(3): 342–348, doi: 10.1111/j.1365-2265.03664.x.
Su B.B., Shi H., Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J. Gastroenterol. 2012; 18(17): 2121–2126, doi: 10.3748/wjg.v18.i17.2121.
Bowen R.C., Little N.A., Harmer J.R., Ma J., Mirabelli L.G., Roller K.D. et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget 2017; 8(19): 32171–32189, doi: 10.18632/oncotarget.16291.
Tan D., Fu Y., Su Q., Wang H. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Medicine 2016; 95(24): e3837, doi: 10.1097/MD.0000000000003837.
Pfaffe T., Cooper-White J., Beyerlein P., Kostner K., Punyadeera C. Diagnostic potential of saliva: current state and future applications. Clin. Chem. 2011; 57(5): 675–687, doi: 10.1373/clinchem.2010.153767.
Liu J., Duan Y. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012; 48(7): 569–577, doi: 10.1016/j.oraloncology.2012.01.021.
Mizukawa N., Sugiyama K., Fukunaga J., Ueno T., Mishima K., Takagi S., Sugahara T. Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res. 1998; 18(6B): 4645–4649.
Lokesh K., Jayanthi K. Saliva: A mirror to health. Int. J. Contemp. Dent. Med. Rev. 2015: 1–3.
Journals System - logo
Scroll to top